Sponsored Links
| Adolor Corporation Completes Enrollment In Phase 2 OIC Program |
 |
 |
 |
| Medical News - GastroIntestinal and Gastroenterology | |||
|
Adolor Corporation (NasdaqGM: ADLR) today announced that it has completed enrollment in its Phase 2 clinical evaluation of ADL5945 in chronic, non-cancer pain patients with opioid-induced constipation (OIC). Adolor is conducting two Phase 2 studies of ADL5945 in OIC patients in parallel. The first study is evaluating two doses of ADL5945 - 0.10 mg and 0... Read more: GastroIntestinal / Gastroenterology News From Medical News Today
|